Clinical Trial Update: Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating autologous bone marrow-derived mesenchymal cells given intravenously in patients with multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Mesenchymal Cells From Autologous Bone Marrow (MACT)

Snippet

Sponsor: Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | Conditions: Multiple Sclerosis | Phase 1, Phase 2 | Status: COMPLETED